top of page
  • Writer's pictureRonald Allan Caluste

A Beacon of Hope: Kisunla and the Fight Against Alzheimer's Disease

Alzheimer's disease, a progressive neurodegenerative disorder, casts a long shadow over millions of families worldwide. Until recently, treatment options focused primarily on managing symptoms rather than slowing the disease's relentless march. However, the recent FDA approval of Kisunla (donanemab) offers a glimmer of hope, marking a significant step forward in the fight against Alzheimer's.

Kisunla: A Targeted Approach

Kisunla belongs to a new class of drugs called antiamyloid therapies. These drugs target the buildup of amyloid beta plaques, a hallmark pathological feature of Alzheimer's disease. The accumulation of these plaques disrupts brain function and is believed to play a crucial role in the disease's progression [1].

Kisunla, specifically, is a monoclonal antibody. These lab-made proteins mimic the body's immune system by attaching to specific targets. In this case, Kisunla binds to amyloid beta plaques, promoting their clearance from the brain [2]. This targeted approach has the potential to slow cognitive decline and improve the quality of life for patients with Alzheimer's disease.

Clinical Trials and Approval

The FDA approval of Kisunla was based on the results of a large, Phase III clinical trial involving over 1,800 participants diagnosed with early-stage Alzheimer's disease [3]. The study compared the effectiveness of Kisunla with a placebo. Patients receiving Kisunla demonstrated a statistically significant reduction in cognitive decline compared to those on the placebo. Additionally, the drug was found to be well-tolerated, with a manageable side effect profile [3].

These promising findings paved the way for the FDA's historic approval of Kisunla in July 2024 [4]. This marks the third antiamyloid therapy approved by the FDA in recent years, offering a much-needed treatment option for patients with early-stage Alzheimer's disease.

Kisunla: Not a Cure, But a Hopeful Step

It's important to understand that Kisunla is not a cure for Alzheimer's disease. However, its ability to slow cognitive decline can offer significant benefits for patients. By delaying the progression of the disease, Kisunla can help individuals maintain their independence for longer, improve their quality of life, and potentially reduce the burden on caregivers.

Furthermore, Kisunla's approval opens new avenues for research in Alzheimer's disease. The success of this targeted therapy paves the way for the development of even more effective medications and combination therapies that could offer even greater benefits to patients.

Looking Forward: Access and Continued Research

Despite the promise of Kisunla, challenges remain. The long-term effects of the drug require further investigation. Additionally, the high cost of these medications raises questions about access and affordability for all patients who could benefit [5].

Moving forward, continued research is essential to optimize the use of Kisunla and develop even more effective treatments. Additionally, ensuring equitable access to these medications is crucial to ensure that the fight against Alzheimer's disease benefits everyone facing this devastating condition.

Kisunla's approval represents a significant milestone in the fight against Alzheimer's disease. While it is not a cure, it offers a much-needed weapon in the arsenal against this debilitating condition. As research continues and access to these medications expands,

Kisunla has the potential to improve the lives of millions living with Alzheimer's disease and offer hope for a future where the disease's grip is loosened.


[1] Alzheimer's Association. (2022, September 29). Alzheimer's disease causes & risk factors.

[2] Eli Lilly and Company. (2024, July 2). Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease.

[3] Food and Drug Administration. (2024, July 1). FDA approves treatment for adults with Alzheimer's disease.

[4] AP News. (2024, July 2). FDA approves a second Alzheimer's drug that can modestly slow disease.

[5] CBS News. (2024, July 4). FDA approves new Alzheimer's treatment, donanemab from Eli Lilly.

3 views0 comments


bottom of page